<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="232">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04456595</url>
  </required_header>
  <id_info>
    <org_study_id>COV-02-IB</org_study_id>
    <nct_id>NCT04456595</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals</brief_title>
  <acronym>PROFISCOV</acronym>
  <official_title>Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butantan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sinovac Life Sciences Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Butantan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III clinical trial to assess efficacy and safety of the Adsorbed COVID-19&#xD;
      (inactivated) vaccine manufactured by Sinovac in health care professionals&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III clinical trial to assess efficacy and safety of the Adsorbed COVID-19&#xD;
      (inactivated) vaccine manufactured by Sinovac in health care professionals.&#xD;
&#xD;
      The study will be double-blind placebo-controlled trial with participants randomly allocated&#xD;
      1:1 to placebo and vaccine arms.&#xD;
&#xD;
      The immunization schedule is two doses intramuscular injections (deltoid) with a 14-days&#xD;
      interval.&#xD;
&#xD;
      For efficacy, the study aims to detect COVID-19 cases, defined as symptomatic SARS-CoV-2&#xD;
      infections, after the second week post-immunization schedule.&#xD;
&#xD;
      For safety and immunogenicity, participants are categorized in two age groups, Adults (18-59&#xD;
      years) and Elderly (60 years and above). Safety database aims to detect adverse reactions&#xD;
      with frequency of 1:1000 or higher in adults and 1:500 in elderly.&#xD;
&#xD;
      All participants will be followed up to 12 months. Interim preliminary efficacy analysis can&#xD;
      be triggered by reaching the target number of 61 cases. Primary efficacy analysis requires&#xD;
      151 cases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of COVID-19 cases after two-doses immunization schedule</measure>
    <time_frame>Two weeks after second dose up to one year after first dose</time_frame>
    <description>Number of virologically-confirmed symptomatic COVID-19 two weeks after second dose of vaccine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events up to seven days after immunization</measure>
    <time_frame>Seven days after each immunization</time_frame>
    <description>Frequency of adverse reaction in the seven days following each immunization per age group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19 cases after two-doses immunization schedule according to previous exposure</measure>
    <time_frame>Two weeks after first dose up to one year after first dose</time_frame>
    <description>Number of virologically-confirmed symptomatic COVID-19 two weeks after second dose of vaccine according to previous exposure to SARS-CoV-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19 cases after 14-days of first immunization</measure>
    <time_frame>Two weeks after last dose uup to one year after first dose</time_frame>
    <description>Number of virologically-confirmed symptomatic COVID-19 two weeks after first dose of vaccine, regardless the vaccination schedule was completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined incidence of SARS-CoV-2 infection</measure>
    <time_frame>Two weeks after second dose up to one year after first dose</time_frame>
    <description>Number of virologically-confirmed and or serologically-confirmed SARS-CoV-2 infections two weeks after first dose of vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe COVID-19 cases after two-doses immunization schedule</measure>
    <time_frame>Two weeks after second dose up to one year after first dose</time_frame>
    <description>Number of virologically-confirmed severe COVID-19 two weeks after second dose of vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events up to 28 days after immunization</measure>
    <time_frame>28 days after each immunization</time_frame>
    <description>Frequency of adverse reaction in the 28 days following each immunization per age group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of severe COVID-19 cases</measure>
    <time_frame>From first vaccination up to one year after first dose</time_frame>
    <description>Frequency of virologically-confirmed severe COVID-19 cases after receiving, at least, one dose of the vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events of special interest after immunization</measure>
    <time_frame>From first vaccination up to one year after first dose</time_frame>
    <description>Frequency of adverse events of special interest after receiving, at least, one dose of the vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate</measure>
    <time_frame>Two weeks after each vaccination</time_frame>
    <description>Number of seroconversion responses to SARS-CoV-2 in the second week after each vaccination per age group in a subset of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated immune profile</measure>
    <time_frame>Two and four weeks afer each vaccination</time_frame>
    <description>Number of cell-mediated immune response against SARS-CoV-2 in the week two and four after the second vaccination per age group in a subset of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity rate</measure>
    <time_frame>Two weeks after second vaccination</time_frame>
    <description>Number of seropositive responses to SARS-CoV-2 in the second week after each vaccination per age group in a subset of participants</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">13060</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Adult - Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aging 18-59 years receiving two doses with 14-days interval of Adsorbed COVID-19 (inactivated) Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly - Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aging 60 years or above receiving two doses with 14-days interval of Adsorbed COVID-19 (inactivated) Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aging 18-59 years receiving two doses with 14-days interval of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aging 60 years or above receiving two doses with 14-days interval of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adsorbed COVID-19 (inactivated) Vaccine</intervention_name>
    <description>Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac</description>
    <arm_group_label>Adult - Vaccine</arm_group_label>
    <arm_group_label>Elderly - Vaccine</arm_group_label>
    <other_name>CoronaVac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac</description>
    <arm_group_label>Adult - Placebo</arm_group_label>
    <arm_group_label>Elderly - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults 18 years of age or older;&#xD;
&#xD;
          2. Healthcare professionals who work in direct contact care of people with possible or&#xD;
             confirmed COVID-19 cases;&#xD;
&#xD;
          3. Agree with periodic contacts by phone or electronic means, and home visits;&#xD;
&#xD;
          4. Show voluntary intention to participate in the study, documented by the informed&#xD;
             consent form signed by participant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. For females: Pregnancy (confirmed by positive beta-hCG test), breastfeeding or intent&#xD;
             to engage in sexual relations with reproductive intent without use of birth control&#xD;
             methods in the three months following vaccination;&#xD;
&#xD;
          2. Evidence of uncontrolled neurological, cardiac, pulmonary, hepatic or renal disease,&#xD;
             according to anamnesis or physical examination. Significant changes in treatment or&#xD;
             hospitalizations due to worsening of the condition in the last three months are&#xD;
             indicators of uncontrolled disease;&#xD;
&#xD;
          3. Diseases with impaired immune system including: neoplasms (except basal cell&#xD;
             carcinoma), congenital or acquired immunodeficiencies and autoimmune diseases not&#xD;
             controlled according to anamnesis or physical examination. Significant changes in&#xD;
             treatment or hospitalizations due to worsening of the condition in the last three&#xD;
             months are indicators of uncontrolled disease;&#xD;
&#xD;
          4. Behavioral, cognitive or psychiatric disease that, in the opinion of the principal&#xD;
             investigator or his or her representative physician, affects the participant's ability&#xD;
             to understand and cooperate with all study protocol requirements;&#xD;
&#xD;
          5. Any alcohol or drug abuse over the 12 months prior to enrollment in the study that has&#xD;
             caused medical, professional or family problems, indicated by clinical history;&#xD;
&#xD;
          6. History of severe allergic reactions or anaphylaxis to the study vaccine or to&#xD;
             components thereof;&#xD;
&#xD;
          7. History of asplenia;&#xD;
&#xD;
          8. Participation in another clinical trial with an investigational product in the six&#xD;
             months prior to enrollment in the study or planned participation in another clinical&#xD;
             trial within the two years following enrollment;&#xD;
&#xD;
          9. Previous participation in a study to evaluate a COVID-19 vaccine or prior exposure to&#xD;
             a COVID-19 vaccine;&#xD;
&#xD;
         10. Use of immunosuppressant therapy regimens within the six months prior to enrollment in&#xD;
             the study for planned use within the two years following enrollment. Immunosuppressant&#xD;
             therapy regimens include: antineoplastic chemotherapy, radiation therapy and&#xD;
             immunosuppressants to induce transplant tolerance, among others.&#xD;
&#xD;
         11. Use of immunosuppressive doses of corticosteroids within the three months prior to the&#xD;
             enrollment in the study and planned use of immunosuppressive doses of corticoids&#xD;
             within the three months following enrollment in the study. Immunosuppressive doses of&#xD;
             corticosteroids will be considered the equivalent prednisone 20 mg/day for adults, for&#xD;
             longer than one week. Continued use of topical or nasal corticosteroids is not&#xD;
             considered an immunosuppressant;&#xD;
&#xD;
         12. Received blood products (transfusions or immunoglobulins) within the three months&#xD;
             prior to enrollment in the study, or planned administration of blood products or&#xD;
             immunoglobulins within the two years following enrollment in the study;&#xD;
&#xD;
         13. Suspected or confirmed fever within the 72 hours prior to vaccination or axillary&#xD;
             temperature greater than 37.8 °C* on the day of vaccination (enrollment may be&#xD;
             postponed until participant has gone 72 hours without fever);&#xD;
&#xD;
         14. Possible or confirmed case of COVID-19 on the day of vaccination (vaccination can be&#xD;
             postponed until the participant completes 72 hours without symptoms or the diagnosis&#xD;
             is ruled out);&#xD;
&#xD;
         15. Received live attenuated virus vaccine or inactivated vaccine within the 28 days or 14&#xD;
             days, respectively, prior to enrollment in the study, or immunization planned within&#xD;
             the 28 days after enrollment in the study;&#xD;
&#xD;
         16. History of bleeding disorder (e.g. factor deficiency, coagulopathy or platelet&#xD;
             disorder), or prior history of significant bleeding or bruising following IM&#xD;
             injections or venipuncture&#xD;
&#xD;
         17. Any other condition that, in the opinion of the principal investigator or his/her&#xD;
             representative physician, could put the safety/rights of potential participants at&#xD;
             risk or prevent them from complying with this protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Palacios, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Butantan Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Palacios, MD, PhD</last_name>
    <phone>551137232121</phone>
    <email>ricardo.palacios@butantan.gov.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universidade de Brasília</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>71691-082</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo Adolfo Sierra Romero, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gustavo Adolfo Sierra Romero, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30750-140</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro M Teixeira, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Mauro M Teixeira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Júlio Müller</name>
      <address>
        <city>Cuiabá</city>
        <state>Mount</state>
        <zip>78048-902</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cor J Fontes, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Maria Aparecida Pedrossian</name>
      <address>
        <city>Campo Grande</city>
        <state>MS</state>
        <zip>79080-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Lúcia Lyrio de Oliveira, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Universidade Federal do Paraná</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Raboni, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sonia Raboni, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Escola da Universidade Federal de Pelotas</name>
      <address>
        <city>Pelotas</city>
        <state>RS</state>
        <zip>96020-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danise S Oliveira, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas da Pontificia Universidade Catolica do Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90619-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabiano Ramos, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Fabiano Ramos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Amor - Fundação Pio XII</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14780-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gecilmara Cristina S Pileggi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da UNICAMP</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083-888</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco H Aoki, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Francisco H Aoki, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>SP</state>
        <zip>14015-069</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo B Coelho, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Eduardo B Coelho, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Infectologia Emílio Ribas</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01246-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiz Carlos Pereira Júnior, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Luiz Carlos Pereira Júnior, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas Clínicas do Instituto Central do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esper Kallas, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Esper Kallas, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Israelita de Ensino e Pesquisa Albert Einstein</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05652-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Fernando Aranha Camargo, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Luis Fernando Aranha Camargo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Municipal de São Caetano do Sul</name>
      <address>
        <city>São Caetano do Sul</city>
        <state>SP</state>
        <zip>09521-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fábio E Leal, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Fábio E Leal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina de São José do Rio Preto - FAMERP</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurício L Nogueira, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Maurício L Nogueira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Infectologia Evandro Chagas - Fiocruz</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>21710-232</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André Siqueira, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>André Siqueira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Palacios R, Patiño EG, de Oliveira Piorelli R, Conde MTRP, Batista AP, Zeng G, Xin Q, Kallas EG, Flores J, Ockenhouse CF, Gast C. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Oct 15;21(1):853. doi: 10.1186/s13063-020-04775-4.</citation>
    <PMID>33059771</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

